To find more information on Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Early Phase Cancer Clinical Trials, including eligibility criteria, click theÌýhyperlinkedÌýLocal Project Reference (LRP)ÌýID, which will take you to the Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Find a Study database.
Ìý
ALLCAR19Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19) | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr Claire Roddie |
Drug Class/ Treatrment: | CAR T-Cell Therapy Expressing CD19 Chimeric Antigen Receptor (CD19CAR) |
Patient Population: |
AdultsÌý>/=16 years old |
Trial Hosted By - Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Cancer Clinical Trials Unit (CCTU) |
NAVAL-1An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr. Kirit Ardeshna |
Drug Class/ Treatrment: | NanatinostatÌý(Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication) |
Patient Population: | Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas |
Trial Hosted By - Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Cancer Clinical Trials Unit (CCTU) |
Ìý
CO43805 | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr WIlliam Townsend |
Drug Class/Treatment: | MosunetuzumabÌý(bispecific CD20-directed CD3 T-cell engager) orÌýGlofitamabÌý(CD20- and CD3- Bispecific Antibody) In Combination withÌýCC-220Ìý(cereblon E3 ligase modulator) + CC-99282Ìý(E3 Ligase Modulator) |
Patient Population: | B-Cell Non-Hodgkin Lymphoma |
Trial Hosted By - NIHR Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH Clinical Research Facility (CRF) |
Ìý